NCT/Study#

NCT04468984 /

M20-178

AbbVie, Protocol: M20-178, PI: Dr. McCloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

AbbVie, Protocol: M20-178, PI: Dr. McCloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

DISEASE GROUP:
Leukemia
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: